Cargando…

A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

BACKGROUND: Diabetes mellitus and concomitant dyslipidemia, being referred to as ‘diabetic dyslipidemia’, are the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balakumar, Pitchai, Mahadevan, Nanjaian, Sambathkumar, Ramanathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875865/ https://www.ncbi.nlm.nih.gov/pubmed/30636619 http://dx.doi.org/10.2174/1874467212666190111165015

Ejemplares similares

Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
por: Samuelsson, O., et al.
Publicado: (2013)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

PPAR α and PPAR γ Polymorphisms as risk factors for Dyslipidemia in a Chinese han population
por: Gu, Shu-Jun, et al.
Publicado: (2014)

MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
por: Wang, Xu, et al.
Publicado: (2017)

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
por: Tian, Siyu, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Contemporary Management of Dyslipidemia
por: Ferraro, Richard A., et al.
Publicado: (2022)

Potent Anti-Diabetic Effects of MHY908, a Newly Synthesized PPAR α/γ Dual Agonist in db/db Mice
por: Park, Min Hi, et al.
Publicado: (2013)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes
por: Piątkowska-Chmiel, Iwona, et al.
Publicado: (2022)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice
por: Boujon, Valérie, et al.
Publicado: (2019)

NPY(1)R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression
por: Wittrisch, Stefanie, et al.
Publicado: (2019)

Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
por: Cariou, Bertrand, et al.
Publicado: (2011)

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
por: Jani, Rajendra H., et al.
Publicado: (2013)

Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial
por: Jain, Nimisha, et al.
Publicado: (2019)

A Mixture of Extracts of Kochia scoparia and Rosa multiflora with PPAR α/γ Dual Agonistic Effects Prevents Photoaging in Hairless Mice
por: Jeon, Hyerin, et al.
Publicado: (2016)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models
por: Jain, Mukul R, et al.
Publicado: (2015)

The Novel PPAR α/γ Dual Agonist MHY 966 Modulates UVB–Induced Skin Inflammation by Inhibiting NF-κB Activity
por: Park, Min Hi, et al.
Publicado: (2013)

Cheonggukjang-Specific Component 1,3-Diphenyl-2-Propanone as a Novel PPARα/γ Dual Agonist: An In Vitro and In Silico Study
por: Arulkumar, Radha, et al.
Publicado: (2021)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
por: Ayza, Muluken Altaye, et al.
Publicado: (2020)

PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
por: Silswal, Neerupma, et al.
Publicado: (2012)

PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia
por: Li, Ke, et al.
Publicado: (2020)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3d4i9ebse716dgv9bibsm8c633